Antibodies that bind to EphA2 and methods of use thereof
Provided herein is disclosure about the development and characterization of an antibody that binds to antigen EphA2 which is present on a variety of human cancers from breast, lung, prostate, and colons. Methods of diagnosing and treating various cancers by using such antibodies directed against this antigen are also disclosed.
1. An isolated nucleic acid sequence that encodes an EphA2 antibody, wherein said antibody specifically binds to EphA2 and comprises the three complementarity determining regions from the heavy chain and the three complementarity determining regions from the light chain of antibody LUCA19 produced by the cell line having ATCC No. PTA-5070.
2. The nucleic acid of claim 1 , wherein the nucleic acid is operably linked to a promoter.
3. The nucleic acid of claim 2 , wherein the promoter and the nucleic acid are contained in an expression vector.
4. The nucleic acid of claim 1 , wherein said EphA2 antibody is an antigen-binding fragment selected from the group consisting of a Fab, a Fab', a F(ab') 2 and a Fv; wherein said antigen binding fragment retains the binding specificity of antibody LUCA19 produced by the cell line having ATCC No. 5070.
5. A cell line transfected, transformed, or infected with a vector containing a nucleic acid of claim 1 .
6. A method for producing a substantially purified immunoglobulin, or an antigen binding fragment thereof, comprising the steps of:
a. Growing a cell line transformed with the nucleic acid of claim 1 under conditions in which the immunoglobulin or antigen binding fragment is expressed; and
b. Harvesting the expressed immunoglobulin or fragment.
7. The method of claim 6 , wherein the cell line is a hybridoma.
8. The nucleic acid of claim 1 , wherein said EphA2 antibody is a humanized antibody.
9. The nucleic acid of claim 8 , wherein said EphA2 antibody is an antigen-binding fragment selected from the group consisting of a Fab, a Fab', a F(ab') 2 and a Fv; wherein said antigen binding fragment retains the binding specificity of antibody LUCA19 produced by the cell line having ATCC No. 5070.
10. An isolated nucleic acid sequence that encodes an EphA2 antibody, wherein said antibody specifically binds to EphA2 and comprises the three complementarity determining regions from the heavy chain and the three complementarity determining regions from the light chain of antibody SPL 1 produced by the cell line having ATCC No. PTA-6059.
11. The nucleic acid of claim 10 , wherein the nucleic acid is operably linked to a promoter.
12. The nucleic acid of claim 11 , wherein the promoter and the nucleic acid are contained in an expression vector.
13. The nucleic acid of claim 10 , wherein said EphA2 antibody is an antigen-binding fragment selected from the group consisting of a Fab, a Fab', a F(ab') 2 and a Fv; wherein said antigen binding fragment retains the binding specificity of antibody SPL1 produced by the cell line having ATCC No. 6059.
14. A cell line transfected, transformed, or infected with a vector containing a nucleic acid of claim 10 .
15. A method for producing a substantially purified immunoglobulin, or an antigen binding fragment thereof, comprising the steps of:
a. Growing a cell line transformed with the nucleic acid of claim 10 under conditions in which the immunoglobulin or antigen binding fragment is expressed; and
b. Harvesting the expressed immunoglobulin or fragment.
16. The method of claim 15 , wherein the cell line is a hybridoma.
17. The nucleic acid of claim 10 , wherein said EphA2 antibody is a humanized antibody.
18. The nucleic acid of claim 17 , wherein said EphA2 antibody is an antigen-binding fragment selected from the group consisting of a Fab, a Fab', a F(ab') 2 and a Fv; wherein said antigen binding fragment retains the binding specificity of antibody SPL1 produced by the cell line having ATCC No. 6059.
19. An isolated nucleic acid sequence that encodes an EphA2 antibody, wherein said antibody specifically binds to EphA2 and comprises the three complementarity determining regions from the heavy chain and the three complementarity determining regions from the light chain of antibody LUCA40 produced by the cell line having ATCC No. PTA-6056.
20. The nucleic acid of claim 19 , wherein the nucleic acid is operably linked to a promoter.
21. The nucleic acid of claim 20 , wherein the promoter and the nucleic acid are contained in an expression vector.
22. The nucleic acid of claim 19 , wherein said EphA2 antibody is an antigen-binding fragment selected from the group consisting of a Fab, a Fab', a F(ab') 2 and a Fv; wherein said antigen binding fragment retains the binding specificity of antibody LUCA40 produced by the cell line having ATCC No. 6056.
23. A cell line transfected, transformed, or infected with a vector containing a nucleic acid of claim 19 .
24. A method for producing a substantially purified immunoglobulin, or an antigen binding fragment thereof, comprising the steps of:
a. Growing a cell line transformed with the nucleic acid of claim 10 under conditions in which the immunoglobulin or antigen binding fragment is expressed; and
b. Harvesting the expressed immunoglobulin or fragment.
25. The method of claim 24 , wherein the cell line is a hybridoma.
26. The nucleic acid of claim 19 , wherein said EphA2 antibody is a humanized antibody.
27. The nucleic acid of claim 26 , wherein said EphA2 antibody is an antigen-binding fragment selected from the group consisting of a Fab, a Fab', a F(ab') 2 and a Fv; wherein said antigen binding fragment retains the binding specificity of antibody LUCA40 produced by the cell line having ATCC No. 6056.
28. An isolated nucleic acid sequence that encodes an EphA2 antibody, wherein said antibody specifically binds to EphA2 and comprises the three complementarity determining regions from the heavy chain and the three complementarity determining regions from the light chain of antibody SG5 produced by the cell line having ATCC No. PTA-7356.
29. The nucleic acid of claim 28 , wherein the nucleic acid is operably linked to a promoter.
30. The nucleic acid of claim 29 , wherein the promoter and the nucleic acid are contained in an expression vector.
31. The nucleic acid of claim 28 , wherein said EphA2 antibody is an antigen-binding fragment selected from the group consisting of a Fab, a Fab', a F(ab') 2 and a Fv; wherein said antigen binding fragment retains the binding specificity of antibody LUCA19 produced by the cell line having ATCC No. 5070.
32. A cell line transfected, transformed, or infected with a vector containing a nucleic acid of claim 28 .
33. A method for producing a substantially purified immunoglobulin, or an antigen binding fragment thereof, comprising the steps of:
a. Growing a cell line transformed with the nucleic acid of claim 28 under conditions in which the immunoglobulin or antigen binding fragment is expressed; and
b. Harvesting the expressed immunoglobulin or fragment.
34. The method of claim 33 , wherein the cell line is a hybridoma.
35. The nucleic acid of claim 28 , wherein said EphA2 antibody is a humanized antibody.
36. The nucleic acid of claim 35 , wherein said EphA2 antibody is an antigen-binding fragment selected from the group consisting of a Fab, a Fab', a F(ab') 2 and a Fv; wherein said antigen binding fragment retains the binding specificity of antibody SG5 produced by the cell line having ATCC No. 7356.